�y•½�¬24”N“x�z
183) �›“y‹�‰ë”ü�AŠ��ì“TŽq�A‘��ê��ˆê�A�•�è—E“ñ�A�‡—t “N–ç�F
‹}�«‹Ç�ЉŠ�ǂɔº‚¤–ò•¨ŠÌ‘ãŽÓŠˆ�«‚̕ϓ®ƒ�ƒJƒjƒYƒ€‚ÌŒŸ“¢.
“ú–{–òŠw‰ï‘æ133”N‰ï�C‰¡•lŽs�C3.27-30, 2013.
182) �›Atsushi Osanaga, Keiichi Makinodan, Tatsuya Sakiyama, Tetsuya Aiba and Yuji Kurosaki:
Evaluation of dynamic diffusion process for developing focally acting DDSs: Improvement of focal bioavailability by topical cooling.
‘æ6‰ñŽŸ�¢‘ã‚ð’S‚¤ŽáŽèˆã—Öò‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€�C‹ž“sŽs�C11.23-24, 2012.
181) �›Yukiko Takahata, Risa Takaki, Mizuki Horiuchi, Soichiro Moriyama, Tetsuya Aiba and Yuji Kurosaki:
Effect of intraperitoneal lipid emulsions on plasma-to-peritoneal transfer of lipophilic drugs in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ27‰ñ”N‰ï�C“Œ‹ž�C11.20-22, 2012.
180) �›Noriko Kajikawa, Masami Doi, Jun-ichi Kusaba, Yuji Kurosaki and Tetsuya Aiba:
Effects of acute local inflammation on the hepatic expressions of the CYP3A subfamily in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ27‰ñ”N‰ï�C“Œ‹ž�C11.20-22, 2012.
179) �›�‚–Ø—�ŽÑ�A�‚”¨—F‹IŽq�A–x“à��Ž÷�A�XŽR‘�ˆê˜Y�A�‡—t “N–ç�A�•�è —E“ñ�F
• �o“à‚É’�“ü‚µ‚½Ž‰–b“û�Ü‚ªŒŒŸ÷’†‹y‚Ñ• �o“à–ò•¨“®‘Ô‚É‹y‚Ú‚·‰e‹¿�Fމ—n�«‚̈قȂé–ò•¨‚ł̔äŠrŒŸ“¢.
‘æ51‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C�¼�]Žs�C11.10-11, 2012.
178) �›“y‹�‰ë”ü�AŠ��ì“TŽq�A‘��ê��ˆê�A�•�è—E“ñ�A�‡—t “N–ç�F
ƒ‰ƒbƒgŠÌCYP3A‘ãŽÓŠˆ�«‚É‹y‚Ú‚·‹}�«‹Ç�ЉŠ�ǂ̉e‹¿.
‘æ51‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C�¼�]Žs�C11.10-11, 2012.
177) �›–q”V’i Œhˆê�A“Œ‰¶”[ Ži�A�èŽR ’B–î�A�‡—t “N–ç�A�•�è —E“ñ�F
Microdialysis–@‚ð—p‚¢‚½–ò•¨‚̋ؓ÷“à‹Ç�Š“®‘Ô•]‰¿:‹Ç�Š—â‹p‚É‚æ‚é‹Ç�Š–ò•¨—˜—p—¦‚Ì‘�‘å.
‘æ28‰ñ“ú–{DDSŠw‰ïŠw�p�W‰ï�CŽD–yŽs�C7. 4-5, 2012.
176) �›�¬�ì�@“Ö�A �X�@‘×—T�A �‚‹´�@•‘�A �‡—t“N–ç�A �•�è—E“ñ�F
޼��—Ö@—p”í•¢Œ^ŠO—pŠî�܂Ƃµ‚Ä‚ÌL-HPCŠÜ�…ƒQƒ‹ƒV�[ƒg‚Ì�»�Ü“I“Á�«•]‰¿.
“ú–{–ò�ÜŠw‰ï‘æ27”N‰ï�C�_ŒËŽs�C5.24-26, 2012.
175) �›Œã“¡—SŽq�A ‘C“c‚ ‚ä‚Ý�A �•ú±—E“ñ�A �‡—t“N–ç�F
ƒ‰ƒbƒg‚É‚¨‚¯‚éƒLƒgƒTƒ“‚ð—p‚¢‚½“ï‹zŽû�«�RƒEƒBƒ‹ƒX–ò‚Ì�Á‰»ŠÇ‹zŽû‰ü‘P.
“ú–{–ò�ÜŠw‰ï‘æ27”N‰ï�C�_ŒËŽs�C5.24-26, 2012.
174) �›�èŽR’B•v�A‰ª ‘åŽk�Aƒg�[ƒ}ƒX�EƒWƒFƒŠƒ}ƒ„�A�‡—t“N–ç�A�•ú±—E“ñ�F
މ–b“û�Ü”÷�¬“§�Í–@�iLipo-MD–@�j‚É‚æ‚é�e–û�«–ò•¨‚Ì‹Ç�Š“®‘Ôƒ‚ƒjƒ^“Á�«‚̉ü‘P.
“ú–{–ò�ÜŠw‰ï‘æ27”N‰ï�C�_ŒËŽs�C5.24-26, 2012.
�y•½�¬23”N“x�z
173) �›‰ª“c�~–F�C‰Í–쌒‘¾˜Y�C�Î�쉷Žq�C�â�]—˜Œb�C�‡—t“N–ç�C�ìú±”ŽŒÈ�C�•�è—E“ñ�F
ƒ‰ƒbƒg”]�Ò�‘‰t‚Ì“d‰ðŽ¿•½�t’²�ß‹@�\‚É‹y‚Ú‚·‹}�«‰Š�ǂ̉e‹¿.
“ú–{–òŠw‰ï‘æ132”N‰ï�CŽD–yŽs�C3.28-31, 2012.
172) �›�‡—t“N–ç�C‘º�ã—RŽ÷�C�´�…�N�³�C�ì“c�_•½�C’†ŽR�^—�Žq�C�¬Š}Œ´–¾”ü�C‰ª“c�~–F�C�•�è—E“ñ�C‰Á—ˆ“c”Ž‹M�F
�V‹KRXRƒAƒSƒjƒXƒg‹y‚Ñ‚»‚Ì—Þ‰�‰»�‡•¨‚̃qƒgŠÌ‚É‚¨‚¯‚é‘ãŽÓ“Á�«‚Ì—\‘ª.
“ú–{–òŠw‰ï‘æ132”N‰ï�CŽD–yŽs�C3.28-31, 2012.
171) �›�•�è—E“ñ�F
ƒgƒ‰ƒCƒAƒ‹•]‰¿‚ÌŠT—v�F�‘—§‘åŠw‚Ì—§�ê‚©‚ç.�iˆê”ʃVƒ“ƒ|ƒWƒEƒ€�u‚U”N�§–òŠw‹³ˆçƒvƒ�ƒOƒ‰ƒ€‚Ì‘æŽOŽÒ•]‰¿�`ƒgƒ‰ƒCƒAƒ‹‚©‚ç–{•]‰¿‚Ö�`�v�Cƒgƒ‰ƒCƒAƒ‹•]‰¿‚ÌŠT—v�j
“ú–{–òŠw‰ï‘æ132”N‰ï�CŽD–yŽs�C3.28-31, 2012.
170) �›Kentaro Kono, Atsuyoshi Okada, Atsuko Ishikawa, Rie Sakae, Hiromu Kawasaki, Yuji Kurosaki and Tetsuya Aiba:
Effect of acute inflammation on lithium disposition to cerebrospinal fluid in rats
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ï�C�L“‡Žs�C11.16-18, 2011.
169) �›Yoshiki Murakami, Yasumasa Shimizu, Kohei Kawata, Mariko Nakayama, Akemi Ogasawara, Yuji Kurosaki, Tetsuya Aiba and Hirotaka Kakuta:
Metabolic properties of novel retinoid X receptor agonists possessing various side chain structures in liver microsomes
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ï�C�L“‡Žs�C11.16-18, 2011.
168) �›Mahira Hashim, Hiroyuki Miyachi, Thomas Jeremiah, Tetsuya Aiba and Yuji Kurosaki:
Studies on the biopharmaceutical characteristics of novel PPAR pan-agonist, TIPP-703, and its pharmaceutical modification to improve intestinal absorption.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ï�C�L“‡Žs�C11.16-18, 2011.
167) �›‰ª“c�~–F�A‰Í–쌒‘¾˜Y�A�Î�쉷Žq�A�â�]—˜Œb�A�ìú±”ŽŒÈ�A�•ú±—E“ñ�A�‡—t“N–ç�F
‹}�«‰Š�ǂɔº‚¤“d‰ðŽ¿‚Ì”]�Ò�‘‰tˆÚ�s“Á�«‚̕ϓ®•]‰¿.
‘æ50‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C�‚�¼Žs�C11.12-13, 2011.
166) �›�´�…�N�³�A‘º�ã—RŽ÷�A�ì“c�_•½�A’†ŽR�^—�Žq�A�¬Š}Œ´–¾”ü�A�•ú±—E“ñ�A�‡—t“N–ç�A‰Á—ˆ“c”Ž‹M�F
�V‹K�œŠi‚ð—L‚·‚éRXRƒAƒSƒjƒXƒg‚Ì‘¤�½�\‘¢‚ÆŠÌ‘ãŽÓŠˆ�«‚Ì‘ŠŠÖ‰ð�Í.
‘æ50‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C�‚�¼Žs�C11.12-13, 2011.
165) �›�‚”¨—F‹IŽq�A–x“à��Ž÷�A�XŽR‘�ˆê˜Y�A�‡—t“N–ç�A�•�è—E“ñ�F
• �o“à�\‘S�g�zŠÂŒŒŠÔ‚Ì–ò•¨ˆÚ�s“®‘Ô‚É‹y‚Ú‚·Ž‰–b“û�܂̉e‹¿�F• �o“à“Š—^Žž‚̈Ú�s“®‘Ô.
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï�C�_ŒË�C10.1-2, 2011.
164) �›�X‘×—T�A�¬�ì“Ö�A�‚‹´•‘�A�XŽR‘�ˆê˜Y�A�㌴–ƒ–¢�A’†ŽR�Ë�]�A�‡—t“N–ç�A�•�è—E“ñ�F
L-HPCŠÜ�…ƒQƒ‹ƒV�[ƒg‚ÌŽ¼��—Ö@—p”í•¢Œ^ŠO—pŠî�܂Ƃµ‚Ä‚Ì�»�Ü“I“Á�«.
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï�C�_ŒË�C10.1-2, 2011.
163) �›�‚‹´�Kˆê�A“n•Ó‘P�Æ�A�•ú±—E“ñ�A’|“à—m•¶�F
‹³ˆç•ª‰È‰ï‚©‚ç‚Ì’ñŒ¾.
“ú–{–ò�ÜŠw‰ï‘æ26”N‰ï�i–òŠw‹³ˆçƒVƒ“ƒ|ƒWƒEƒ€�u–òŠw•”‹³ˆç‚É‘±‚�V‘åŠw‰@‰Û’ö‚ł̋³ˆç‚ÆŒ¤‹†�FŠî‘b‚Æ‚µ‚Ă̊w•”‹³ˆç‚©‚ç�V�¶‘åŠw‰@‹³ˆç‚Ö�v�j�C“Œ‹ž�C5.29-31, 2011.
162) �›–q”V’iŒhˆê�A“Œ‰¶”[�@Ži�A‘º�ã�m”ü�A�‡—t“N–ç�A�•ú±—E“ñ�F
–ò•¨‚̋ؓ÷“àŠgŽU�E•ª•z“®‘Ô‚É‹y‚Ú‚·ŒŒ—¬—ʂ̉e‹¿�F‹Ç�Š—â‹pŽž‚Ì“®‘Ô“Á�«.
“ú–{–ò�ÜŠw‰ï‘æ26”N‰ï�C“Œ‹ž�C5.29-31, 2011.
�@�@�@�@�@
�y•½�¬22”N“x�z
161) �›�•ú±—E“ñ�A•x‰ª‰À‹v�AŽO“c’q•¶�A–k‘º‰À‹v�F
�‘—§‘åŠw‚É‚¨‚¯‚é�u’·Šú‰Û‘茤‹†‹y‚уAƒhƒoƒ“ƒXƒg‹³ˆçƒvƒ�ƒOƒ‰ƒ€�v‚ÌŒ»�ó.
“ú–{–òŠw‰ï‘æ131”N‰ï�iƒVƒ“ƒ|ƒWƒEƒ€�u�擱“I–ò�ÜŽt—{�¬‚ÉŒü‚¯‚½ŽÀ‘H“IƒAƒhƒoƒ“ƒXƒg‹³ˆçƒvƒ�ƒOƒ‰ƒ€‚Ì‹¤“¯ŠJ”�v�j�C�ɪŽs�C3.28-31, 2011.
160) �›Š��ì“TŽq�A‘��ê��ˆê�A�o‰H—SŠî�A�‡—t“N–ç�A�ì�蔎ŒÈ�A�•ú±—E“ñ�F
ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ŠÌ‘ãŽÓ�y‘f‚Ì”Œ»‚É‹y‚Ú‚·‹}�«�t•s‘S‚̉e‹¿.
“ú–{–òŠw‰ï‘æ131”N‰ï�C�ɪŽs�C3.28-31, 2011.
159) �›Œã“¡—SŽq�A‘C“c‚ ‚ä‚Ý�A�‡—t“N–ç�A�•ú±—E“ñ�F
ƒ‰ƒbƒg‚É‚¨‚¯‚éƒLƒgƒTƒ“‚̃AƒVƒNƒ�ƒrƒ‹�Á‰»ŠÇ‹zŽû‘£�i‹@�\‚ÌŒŸ“¢.
“ú–{–òŠw‰ï‘æ131”N‰ï�C�ɪŽs�C3.28-31, 2011.
158) �›Š��ì“TŽq�A‘��ê��ˆê�A�o‰H—SŠî�A�‡—t“N–ç�A�ì�蔎ŒÈ�A�•ú±—E“ñ�F
ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ŠÌ‘ãŽÓŠˆ�«‚É‹y‚Ú‚·‹}�«�t•s‘S‚̉e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C•ÄŽqŽs�C11.6-7, 2010.
157) �›‰ª�@‘åŽk�A�¬—Ñ�@“O�A�‡—t“N–ç�A�•ú±—E“ñ�F
މ–b“û�Ü‚ð—p‚¢‚½”÷�¬“§�Í–@�iLipo-MD–@�j�F–ò•¨‚ÌŽ‰—n�«‚ª“§�Í“Á�«‚É‹y‚Ú‚·‰e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C•ÄŽqŽs�C11.6-7, 2010.
156) �›�‚”¨—F‹IŽq�A�XŽR‘�ˆê˜Y�A–x“à��Ž÷�A�‡—t“N–ç�A�•ú±—E“ñ�F
މ–b“û�Ü‚ð—p‚¢‚½• –Œ“§�Í‚ªŽ‰—n�«–ò•¨‚ÌŒŒŸ÷’†”Z“x�„ˆÚ‚É‹y‚Ú‚·‰e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C•ÄŽqŽs�C11.6-7, 2010.
155) �›Œã“¡—SŽq�A‘C“c‚ ‚ä‚Ý�A�‡—t“N–ç�A�•ú±—E“ñ�F
In vivo‚É‚¨‚¯‚éƒLƒgƒTƒ“‚̃AƒVƒNƒ�ƒrƒ‹‹zŽû‘£�i‹@�\‚ÌŒŸ“¢.
‘æ49‰ñ“ú–{–òŠw‰ï�E“ú–{–ò�ÜŽt‰ï�E“ú–{•a‰@–ò�ÜŽt‰ï’†�‘Žl�‘Žx•”Šw�p‘å‰ï�C•ÄŽqŽs�C11.6-7, 2010.
154) �›Jun-ichi Kusaba, Noriko Kajikawa, Yuki Izuwa, Tetsuya Aiba, Hiromu Kawasaki and Yuji Kurosaki:
Altered drug metabolizing activity of hepatic CYP3A subfamily in rats with acute renal failure.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ25‰ñ”N‰ï�C“Œ‹ž�C10.7-9, 2010.
153) �›Tsukasa Higashionna, Hitomi Murakami, Keiichi Makinodan, Kozue Kanda, Mayu Shibata, Tetsuya Aiba and Yuji Kurosaki:
Microdialysis study in evaluation of intramuscular lateral distribution profiles of topically administered drugs in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ25‰ñ”N‰ï�C“Œ‹ž�C10.7-9, 2010.
152) �›ê “c�’Žu�A�㓇 ’q�A�²“¡’q�º�A�‡—t“N–ç�A�•�è—E“ñ�A�¼‰i �®�A�ç“°”N�º�F
�¬Ž™‚É‚¨‚¯‚éƒeƒCƒRƒvƒ‰ƒjƒ“‚Ì•ê�W’c–ò•¨“®‘Ô‰ð�Í�|ŒŒ’†”Z“x‚É‹y‚Ú‚·Šî‘b޾г‚̉e‹¿�|.
‘æ27‰ñ“ú–{‚s‚c‚lŠw‰ï�EŠw�p‘å‰ï�CŽD–yŽs�C6.26-27, 2010.
151) �›�X�@‘×—T�A�XŽR‘�ˆê˜Y�A�㌴–ƒ–¢�A’†ŽR�Ë�]�A�‡—t“N–ç�A�•ú±—E“ñ�F
L-HPCŠÜ�…ƒQƒ‹ƒV�[ƒg‚Ì’²�»‚Ɣ핢Œ^ŠO—pŠî�܂Ƃµ‚Ä‚Ì�»�Ü“I“Á�«•]‰¿.
“ú–{–ò�ÜŠw‰ï‘æ25”N‰ï�C“¿“‡Žs�C5.12-14, 2010.
150) �›‘C“c‚ ‚ä‚Ý�A�‡—t“N–ç�A�•ú±—E“ñ�F
In vivo‚É‚¨‚¯‚é“ï‹zŽû�«�RƒEƒBƒ‹ƒX–ò‚̃oƒCƒIƒAƒxƒCƒ‰ƒrƒŠƒeƒB‰ü‘P‚ÌŽŽ‚Ý.
“ú–{–ò�ÜŠw‰ï‘æ25”N‰ï�C“¿“‡Žs�C5.12-14, 2010.